Revumenib (SNDX-5613)

Menin Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
AUGMENT-101-2A
(monotherapy)
MLLr ALL/MPAL
AUGMENT-101-2B
(monotherapy)
MLLr AML
AUGMENT-101-2C
(monotherapy)
mNPM1 AML
AUGMENT-102
(chemotherapy combination)
MLLr ALL/MPAL/AML,
mNPM1 AML

Axatilimab (SNDX-6352)

CSF-1R mAB
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
AGAVE-201
(monotherapy)
Chronic GVHD
SNDX-6352-0503
(monotherapy)
Chronic GVHD

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor
PreClin
Phase 1
Phase 2
Pivotal
Indication(s)
Entinostat
Under review

Revumenib (SNDX-5613)

Menin Inhibitor

AUGMENT-101-2A

MLLr ALL/MPAL

Pivotal

AUGMENT-101-2B

MLLr AML

Pivotal

AUGMENT-101-2C

mNPM1 AML

Pivotal

AUGMENT-102

MLLr ALL/MPAL/AML,
mNPM1 AML

Phase 1

Axatilimab (SNDX-6352)

CSF-1R mAB

AGAVE-201

Chronic GVHD

Pivotal

SNDX-6352-0503

Chronic GVHD

Phase 2

Entinostat (SNDX-275)

Class 1 HDAC Inhibitor

Entinostat

Under Review